EXAS - Exact Sciences Corporation

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
112.79
+1.34 (+1.20%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close111.45
Open112.53
Bid90.00 x 1000
Ask0.00 x 1000
Day's Range110.32 - 113.75
52 Week Range47.78 - 117.98
Volume757,979
Avg. Volume1,737,670
Market Cap14.566B
Beta (3Y Monthly)2.38
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
All
News
Press Releases
  • Exact Sciences Advances Fight Against Colorectal Cancer With Opening Of New Laboratory
    PR Newswire13 hours ago

    Exact Sciences Advances Fight Against Colorectal Cancer With Opening Of New Laboratory

    MADISON, Wis., June 26, 2019 /PRNewswire/ -- Less than 20 months after breaking ground, Exact Sciences today opened the doors on its new, 169,000 square foot clinical laboratory and warehouse on the City of Madison's near west side. Exact Sciences is a biotechnology company focused on delivering life-changing innovations in earlier cancer detection. The laboratory opened Wednesday will process Cologuard, the company's colorectal cancer screening test.

  • Exact Sciences to participate in June investor conferences
    PR Newswire27 days ago

    Exact Sciences to participate in June investor conferences

    MADISON, Wis., May 31, 2019 /PRNewswire/ -- Exact Sciences Corp. (EXAS) today announced that company management will be presenting at the following investor conferences and invited investors to participate by webcast. The webcast can be accessed in the investor relations section of Exact Sciences' website at www.exactsciences.com. Exact Sciences Corp. is a molecular diagnostics company focused on the early detection and prevention of some of the deadliest forms of cancer.

  • Exact Sciences Advances Pipeline Capabilities with Mayo Clinic
    PR Newswirelast month

    Exact Sciences Advances Pipeline Capabilities with Mayo Clinic

    SAN DIEGO, May 20, 2019 /PRNewswire/ -- Early research using blood-based methylated DNA markers, identified through the longstanding collaboration between Exact Sciences and Mayo Clinic, demonstrates a potential to achieve 92% sensitivity and 92% specificity for detecting the most common type of pancreatic cancer. Researchers presented the findings at Digestive Disease Week (DDW) 2019, the largest international gathering of physicians, researchers and academics in the fields of gastroenterology, hepatology, endoscopy and gastrointestinal surgery. "These pancreatic cancer data showcase the strength of our marker discovery collaboration with Mayo Clinic, a partnership that is fueling our product pipeline," said Kevin Conroy, chairman and CEO of Exact Sciences.

  • Exact Sciences Presents New Data Reinforcing Performance of Cologuard®
    PR Newswirelast month

    Exact Sciences Presents New Data Reinforcing Performance of Cologuard®

    SAN DIEGO, May 17, 2019 /PRNewswire/ -- New research from Exact Sciences and Mayo Clinic demonstrates the ability of Cologuard to both screen large patient populations and consistently help detect colorectal cancers and pre-cancers regardless of lesion location. The findings, presented at Digestive Disease Week (DDW) 2019, reinforce the role of Cologuard in improving colorectal cancer screening rates and patient outcomes. Despite recent efforts to positively impact colorectal cancer screening rates in the US, one-in-three Americans ages 50 to 75 are not up to date with recommended screening.i New research suggests the Cologuard test can help screen more people.

  • Exact Sciences to participate in May investor conferences
    PR Newswire2 months ago

    Exact Sciences to participate in May investor conferences

    MADISON, Wis., May 1, 2019 /PRNewswire/ -- Exact Sciences Corp. (EXAS) today announced that company management will be presenting at the following investor conferences and invited investors to participate by webcast. The webcast can be accessed in the investor relations section of Exact Sciences' website at www.exactsciences.com. Exact Sciences Corp. is a molecular diagnostics company focused on the early detection and prevention of some of the deadliest forms of cancer.

  • First-quarter revenue and Cologuard test volume increased 79 percent to $162 million and 334,000, respectively
    PR Newswire2 months ago

    First-quarter revenue and Cologuard test volume increased 79 percent to $162 million and 334,000, respectively

    - Estimated Cologuard market share increased to 4.6 percent during the first quarter - Nearly 14,000 health care providers ordered their initial Cologuard test during the first quarter, and more than 160,000 ...

  • ACCESSWIRE2 months ago

    EXACT Sciences Corp. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / April 30, 2019 / EXACT Sciences Corp. (NASDAQ: EXAS ) will be discussing their earnings results in their 2019 First Quarter Earnings to be held on April 30, 2019 at 5:00 PM ...

  • Exact Sciences schedules first-quarter 2019 earnings call
    PR Newswire3 months ago

    Exact Sciences schedules first-quarter 2019 earnings call

    MADISON, Wis., Apr. 8, 2019 /PRNewswire/ -- Exact Sciences Corp. (EXAS) today announced that the company plans to release its first-quarter 2019 financial results after the close of the U.S. financial markets on Apr. 30, 2019. Following the release, company management will host a webcast and conference call at 5 p.m. ET to discuss financial results and business progress. A replay of the conference call will be available by calling 800-585-8367 domestically or 416-621-4642 internationally.

  • Kathleen Sebelius Appointed to Exact Sciences Board
    PR Newswire3 months ago

    Kathleen Sebelius Appointed to Exact Sciences Board

    MADISON, Wis., March 19, 2019 /PRNewswire/ -- Kathleen Sebelius, the 21st Secretary of the U.S. Department of Health and Human Services (HHS) from April 2009 to June 2014 and governor of Kansas from 2003 to 2009, joined the Board of Directors of Exact Sciences Corp. (EXAS), a leader in detecting cancer at its earliest, most treatable stages. Based in Madison, Wisconsin, Exact Sciences delivers life-changing innovations in earlier cancer detection and guidance to give people the confidence to make more effective decisions." alt="Kathleen Sebelius, the 21st Secretary of the U.S. Department of Health and Human Services from April 2009 to June 2014 and governor of Kansas from 2003 to 2009, joined the Board of Directors of Exact Sciences Corp. (EXAS) in March 2019.

  • Exact Sciences Announces Upsizing and Pricing of 0.3750% Convertible Senior Notes Due 2027
    PR Newswire4 months ago

    Exact Sciences Announces Upsizing and Pricing of 0.3750% Convertible Senior Notes Due 2027

    MADISON, Wis., March 6, 2019 /PRNewswire/ -- Exact Sciences Corporation (EXAS) announced today that it has priced its underwritten public offering of 0.3750% convertible senior notes due 2027 (the "Notes") and upsized the offering from $600 million to $650 million aggregate principal amount.  The Company has granted the underwriter a 30-day option to purchase up to an additional $97.5 million aggregate principal amount of the Notes solely to cover over-allotments, if any. The Notes will be senior unsecured obligations of the Company and will bear interest at a rate of 0.3750% per annum.  Interest on the Notes will be payable semi-annually in arrears on March 15 and September 15 of each year, beginning September 15, 2019. The Notes will be convertible into cash, shares of the Company's common stock (and, if applicable, cash in lieu of any fractional share), or a combination thereof, at the Company's election.  The initial conversion rate will be 8.9554 shares of the Company's common stock per $1,000 principal amount of Notes, which is equivalent to an initial conversion price of approximately $111.6645 per share.

  • Exact Sciences Announces Offering of $600 Million Convertible Senior Notes Due 2027
    PR Newswire4 months ago

    Exact Sciences Announces Offering of $600 Million Convertible Senior Notes Due 2027

    MADISON, Wis., March 5, 2019 /PRNewswire/ -- Exact Sciences Corporation (EXAS) (the "Company") today announced an underwritten public offering of $600 million aggregate principal amount of convertible senior notes due 2027 (the "Notes") pursuant to an effective shelf registration statement filed with the Securities and Exchange Commission (the "SEC") on Form S-3. The Company has also granted the underwriter a 30-day option to purchase up to an additional $90.0 million aggregate principal amount of the Notes.  Concurrently with this offering, in separate transactions, the Company also expects to enter into agreements with certain holders of its 1.0% Convertible Senior Notes due in January 2025 (the "2025 Notes") to exchange an aggregate of approximately 50% of the outstanding principal amount of such notes for consideration consisting of cash, shares of the Company's common stock or a combination thereof.

  • GlobeNewswire4 months ago

    Market Trends Toward New Normal in Eaton Corporation, Kite Realty Group Trust, Intercontinental Exchange, SS&C Technologies, Exact Sciences, and Oshkosh — Emerging Consolidated Expectations, Analyst Ratings

    NEW YORK, March 04, 2019 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.

  • Exact Sciences to participate in March investor conferences
    PR Newswire4 months ago

    Exact Sciences to participate in March investor conferences

    MADISON, Wis., March 1, 2019 /PRNewswire/ -- Exact Sciences Corp. (EXAS) today announced that company management will be presenting at the following investor conferences and invited investors to participate by webcast. The webcast can be accessed in the investor relations section of Exact Sciences' website at www.exactsciences.com. Exact Sciences Corp. is a molecular diagnostics company focused on the early detection and prevention of some of the deadliest forms of cancer.

  • Cologuard Helps Screen Two Million People for Colorectal Cancer
    PR Newswire4 months ago

    Cologuard Helps Screen Two Million People for Colorectal Cancer

    MADISON, Wis., Feb. 27, 2019 /PRNewswire/ -- In less than five years, more than two million Americans have screened for colorectal cancer with Cologuard. Exact Sciences Corp., which created the groundbreaking product with Mayo Clinic, processed more than one million Cologuard tests in the last year alone.

  • Total 2018 revenue increased 71 percent to $454 million, and 934,000 people were screened with Cologuard
    PR Newswire4 months ago

    Total 2018 revenue increased 71 percent to $454 million, and 934,000 people were screened with Cologuard

    - Fourth quarter revenue increased 64 percent to $143.0 million - Fourth quarter Cologuard test volume increased 66 percent to 292,000 completed tests, expanding estimated market share to 4.1 percent - ...

  • GlobeNewswire4 months ago

    Cutera Appoints Katherine Zanotti and Joseph Whitters to its Board of Directors

    BRISBANE, Calif., Feb. 20, 2019 -- CUTERA, INC., (Nasdaq: CUTR) (“Cutera” or the “Company”) a leading provider of laser, light and other energy-based aesthetic systems for.

  • Exact Sciences schedules fourth-quarter, full-year 2018 earnings call
    PR Newswire5 months ago

    Exact Sciences schedules fourth-quarter, full-year 2018 earnings call

    MADISON, Wis., Feb. 4, 2019 /PRNewswire/ -- Exact Sciences Corp. (EXAS) today announced that the company plans to release its fourth-quarter and full-year 2018 financial results after the close of the U.S. financial markets on Feb. 21, 2019. Following the release, company management will host a webcast and conference call at 5 p.m. ET to discuss financial results and business progress.

  • GlobeNewswire5 months ago

    Analysis: Positioning to Benefit within Rollins, Hospitality Properties Trust, Exact Sciences, Tenet Healthcare, Entergy, and Calithera Biosciences — Research Highlights Growth, Revenue, and Consolidated Results

    NEW YORK, Jan. 28, 2019 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.

  • ACCESSWIRE6 months ago

    Today's Research Reports on Trending Tickers: Exact Sciences and Illumina

    NEW YORK, NY / ACCESSWIRE / January 7, 2019 / U.S. markets surged on Friday as employment data came in well above expectations. The Bureau of Labor Statistics reported 312,000 jobs were added in December, ...

  • Exact Sciences to report $454-455M in total revenue, 71-percent growth for 2018
    PR Newswire6 months ago

    Exact Sciences to report $454-455M in total revenue, 71-percent growth for 2018

    MADISON, Wis., Jan. 6, 2019 /PRNewswire/ -- Exact Sciences Corp. (EXAS) today announced that the company expects to report revenue between $142.5 million and $143.5 million for the fourth quarter ended Dec. 31, 2018, an increase of 64 percent from the same quarter of 2017. The company completed approximately 292,000 Cologuard tests during the fourth quarter of 2018, which represents 66-percent growth from the same period of 2017. Nearly 15,000 health care providers ordered Cologuard for the first time during the fourth quarter of 2018.

  • PR Newswire6 months ago

    Exact Sciences to participate in J.P. Morgan Healthcare Conference

    MADISON, Wis., Dec. 20, 2018 /PRNewswire/ -- Exact Sciences Corp. (EXAS) today announced that company management will be presenting at the following investor conference and invited investors to participate by webcast. The webcast can be accessed in the investor relations section of Exact Sciences' website at www.exactsciences.com. Exact Sciences Corp. is a molecular diagnostics company focused on the early detection and prevention of the deadliest forms of cancer.

  • ACCESSWIRE6 months ago

    Today's Research Reports on Trending Tickers: Neogen and Exact Sciences

    NEW YORK, NY / ACCESSWIRE / December 13, 2018 / U.S. equities closed higher on Wednesday amidst renewed hopes over the U.S.-China trade talks. According to a report in Wall Street Journal, China is working ...

  • ACCESSWIRE7 months ago

    Today’s Research Reports on Stocks to Watch: OPKO Health and Exact Sciences

    NEW YORK, NY / ACCESSWIRE / November 13, 2018 / OPKO Health was seeing big gains in Monday’s session on a stellar third quarter report. Shares of Exact Sciences Corp. were plummeting despite any remarkable ...

  • PR Newswire8 months ago

    Exact Sciences to participate in two November investor conferences

    MADISON, Wis., Nov. 9, 2018 /PRNewswire/ -- Exact Sciences Corp. (EXAS) today announced that company management will be presenting at the following investor conference during November and invited investors to participate by webcast. Exact Sciences Corp. is a molecular diagnostics company focused on the early detection and prevention of the deadliest forms of cancer. The company has exclusive intellectual property protecting its non-invasive, molecular screening technology for the detection of colorectal cancer.

  • GlobeNewswire8 months ago

    Report: Exploring Fundamental Drivers Behind MRC Global, Exact Sciences, Owens-Illinois, Copart, Cognizant Technology Solutions, and Owens & Minor — New Horizons, Emerging Trends, and Upcoming Developments

    NEW YORK, Nov. 05, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.